Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...

Novartis NOVN-2.46%decrease; red down pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...

According to iSpot.TV’s analysis of January TV drug ad spending data, Novartis’ prostate cancer drug Pluvicto swooped in to take the No. 1 spot on the list, with more than $47 million spent ...

Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we ...

But Steinfeld is gearing up for another arena. Steinfeld is teaming up with pharmaceutical company Novartis to raise awareness about breast cancer with a bold and empowering commercial that will ...

Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late ...

with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. The drugmaker’s first-ever Super Bowl ad is set to ...